Company Overview
Snapshot
Founded in August 2016 by Nimrod Lev, Ahinoam Lev Sagie, and Meny Lev Sagie, GynTools operates with 1-10 employees. The company has raised $4.38 million across 9 funding rounds and secured a grant from Google AI Startup Fund in May 2024.
Business overview
GynTools develops GYNI, an AI-based, accurate, and rapid point-of-care diagnostic system for vaginitis, a common gynecological problem often misdiagnosed. The company's core technology leverages artificial intelligence and deep learning to provide quick diagnoses from swab samples. With AMAR & CE approval, GynTools is commercializing its product in Israel and Europe, with plans for US FDA submission. It targets the digital healthcare and medical technologies markets, serving healthcare providers, insurance companies, and women.
Strategic signal
GynTools won the 2024 'Rising Startup' Asper Prize from the Hebrew University of Jerusalem in June 2024, receiving 100,000 shekels (approximately $27,000). This award validates the company's innovative AI-driven diagnostic tool for vaginal infections and signals strong academic and institutional recognition of its potential impact in women's health diagnostics.
Log in to access full profile ›Company Intelligence Q&A
- What is GynTools' primary product?
- GynTools' primary product is GYNI, an AI-based diagnostic system designed for the rapid and accurate detection of vaginitis, a common gynecological condition.
- When was GynTools founded and by whom?
- GynTools was founded in August 2016 by co-founders Nimrod Lev, Ahinoam Lev Sagie, and Meny Lev Sagie.
- Has GynTools received any recent grants or awards?
- Yes, GynTools won the 2024 'Rising Startup' Asper Prize from the Hebrew University of Jerusalem in June 2024, receiving 100,000 shekels. Additionally, in May 2024, the company secured a grant from Google AI Startup Fund.
- What is the total capital raised by GynTools?
- GynTools has raised a total of $4.38 million across 9 funding rounds.
- What is the regulatory status of GynTools' product?
- GynTools' product, GYNI, has received AMAR & CE approval and the company is preparing for US FDA submission under 510(k) & CLIA waiver.